Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.60 |
| ▸ | SGK1 | O00141 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3526077 | 0.92 | MAPK14 (0.74) | MAPK14CYP2C9HSPB1MAPK11MAPK13 | |
| SCHEMBL3523610 | 0.91 | MAPK14 (0.68) | MAPK14CYP2C9HSPB1MAPK11MAPK13 | |
| SCHEMBL3526849 | 0.90 | MAPK14 (0.67) | MAPK14CYP2C9HSPB1MAPK11MAPK13 | |
| SCHEMBL3525332 | 0.89 | MAPK14 (0.70) | MAPK14CYP2C9HSPB1MAPK11MAPK13 | |
| SCHEMBL3523382 | 0.89 | MAPK14 (0.65) | MAPK14CYP2C9HSPB1MAPK11MAPK13 | |
| SCHEMBL3526283 | 0.87 | MAPK14 (0.72) | MAPK14CYP2C9HSPB1MAPK11MAPK13 | |
| SCHEMBL13546255 | 0.86 | MAPK14 (0.70) | MAPK14CYP2C9HSPB1MAPK11MAPK13 | |
| SCHEMBL3524761 | 0.83 | MAPK13 (0.71) | MAPK14CYP2C9HSPB1MAPK11MAPK13 | |
| SCHEMBL3524006 | 0.83 | MAPK14 (0.67) | MAPK14CYP2C9HSPB1MAPK11MAPK13 | |
| SCHEMBL3528047 | 0.83 | MAPK13 (0.72) | MAPK14CYP2C9HSPB1MAPK11MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | claimed |
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | SMITHKLINE BEECHAM CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1531812-B1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS | SMITHKLINE BEECHAM CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | SMITHKLINE BEECHAM CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | MAPK7, CNKSR1, MAPK1 | MAPK14 11/4885CYP2C9 2502/4885HSPB1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.